SEOUL, KOREA / ACCESSWIRE / September 29, 2020 / As of the 26th of August 2020, Joonghun Pharmaceutical's (CEO Sukjoon Yoon) 'Lorient' a cross-linked hyaluronic acid dermal filler has received the 'CE mark' opening the doors to selling the product in the European market.
Lorient is premium dermal filler introduced by Joonghun Pharmaceutical for the improvement of facial wrinkle improvement. Previously, Lorient without lidocaine (local anesthetic) received the CE mark, but this time Lorient containing lidocaine succeeded in getting approval for the CE mark.
'CE mark' is a European integrated standard certification mark that proves safety, quality and technology suitable for global standards. The acquisition of the CE mark for Joonghun Pharmaceutical is the result of many years of research and investment into hyaluronic acid, and quality control (QC) capability in accordance with GMP (Good Manufacturing Practice) for pharmaceuticals and medical devices.
Joonghun Pharmaceutical notes, "As Lorient has received the CE mark for both products with and without lidocaine, it has once again proven to be a high-quality filler that will soon be leading the global beauty market".
Joonghun Pharmaceutical has made significant efforts for Lorient to be premium filler. First, the safety and efficacy of Lorient has been verified through comparative clinical trials. In addition, STORMTM technology, a unique technology of Joonghun Pharmaceutical, effectively removes impurities that cause product related negative side effects. Joonghun Pharmaceutical has also succeeded in reducing pain during the injection and improving the injection force to be less than 9 newtons, maximizing ease of use and efficacy.
The Lorient product line consists of 6 products, 3 of which do not have lidocaine named 'Lorient Pure' and the remaining 3 with lidocaine named 'Lorient'.
Joonghun Pharmaceutical, founded in 2014, has registered more than 100 products and has a lineup of quality prescription hyaluronic acid injections that also undergo strict production management for use in orthopedic hospitals.
The CEO of Joonghun Pharmaceutical, Sukjoon Yoon, states "Lorient is a product that has succeeded in significantly lowering the level of impurities compared to its competitors through strict process management and adherence to Medical Device and Pharmaceutical GMP standards. We considered the safety of Lorient to be our top priority so that even those who are new to filler treatment can experience it without fear of any negative side effects".
Joonghun Pharmaceutical is currently undergoing preparations for the release of this product scheduled for early October.
Media Contact: Company: Joonghun Pharmaceutical Co., Ltd. Contact: Media Team Tel: +82-2-2138-8114 E-mail: lorient-filler@joonghun.com Website: http://www.joonghun.com/ Address: 15, Gukhoe-daero 62-gil, Yeongdeungpo-gu, Seoul, Korea
SOURCE: Joonghun Pharmaceutical Co., Ltd.
View source version on accesswire.com: https://www.accesswire.com/608249/Joonghun-Pharmaceutical-Lorient-Dermal-Filler-Receives-CE-Mark-Approval
As we move toward the end of Q2, it’s time to start thinking about earnings. Looking back at the quarter, analysts are predicting earnings growth of 8%, which may rise to 11% heading into next year. It’s a rosy picture, but it’s also not a sure thing. GDP contracted in Q1, by nearly 1.5%, and some estimates are showing 0% growth in Q2. Such results would meet the technical definition of a recession – and recession is hardly the usual environment to find robust earnings growth. Looking at current
Nuclear submarine supplier to be sold to US buyer after diplomatic row Russian default expected within days Retail sales volumes down 0.5pc in May FTSE 100 rises strongly Ambrose Evans-Pritchard: The pro-Brussels establishment is painting Brexit as an economic disaster to reverse it Sign up here for our daily business briefing newsletter
When you need another stream of income for retirement, you might consider an annuity. You purchase the annuity from an insurance company and receive payments back at a later date. Before buying an annuity, it's important to consider how much … Continue reading → The post How Much Does a $300,000 Annuity Pay Per Month? appeared first on SmartAsset Blog.
Shares of the specialty pharmaceutical company Bausch Health Companies (NYSE: BHC) are surging today in response to the news that Joseph Papa has resigned from the board of directors effective immediately. Over the past six years, Papa has been instrumental in lowering the company's sky-high debt and keeping it out of bankruptcy court. Bausch said in a statement Thursday evening that billionaire hedge fund manager John Paulson will fill the vacant board position.
In this article, we will take a look at 10 value stocks to buy according to billionaire David Tepper. If you want to skip our discussion on Tepper’s history and his hedge fund’s performance, go directly to 5 Value Stocks to Buy According to Billionaire David Tepper. With a net worth of $16.7 billion, David […]
“Time is running out for cash-burning companies kept afloat with easy access to capital,” New Constructs CEO David Trainer said in a Thursday research note.
High-yield dividend stocks are a major component of my stock portfolio. Here are three income stocks that have room for solid gains in the next year and even better gains over the long run. The blue-chip business development company (BDC) Main Street Capital (NYSE: MAIN) has held up better than the S&P 500 index, which is down 21% so far this year.
Mr Musk now has access to real-time data that could be the last hurdle ahead of his buyout
The days of Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL) stock trading above $2,000 are numbered. Investors often eagerly anticipate stock splits because they think shares could take off after the split. Let's first address the significance (or lack thereof) of stock splits.
Tesla plant near Shanghai is going to shut down temporarily, according to reports. On Wednesday, Reuters reported that Tesla (ticker: TSLA) will shut down production in China for a couple of weeks at the start of July to upgrade equipment. Tesla didn’t return a request for comment.
In this article, we will look at 10 stocks to profit from inflation. If you want to explore similar stocks, you can also read 5 Stocks to Profit from Inflation. Billionaire investor and hedge fund manager of the world’s largest hedge fund, Bridgewater Associates, Ray Dalio shared his views on the current economic situation that […]
Energy prices are high. But bargain-hunter Buffett continues to bet on big oil.
The merger between the special-purpose acquisition company Gores Guggenheim and the electric-vehicle company coming from Volvo is done.
At current levels, investors need a 7% to 8% return just to preserve their wealth.
Shares of CalAmp (NASDAQ: CAMP) were tumbling today after the company reported first-quarter results that missed Wall Street's top- and bottom-line expectations. CalAmp reported a non-GAAP (adjusted) loss per share of $0.10 in the quarter, which was much worse than analysts' consensus estimate of a loss of $0.03. The company's revenue of $64.7 million -- a decrease of nearly 19% from the year-ago quarter -- was also below Wall Street's average estimate of $69.4 million.
As Netflix cuts costs to ease subscriber-loss pains, more jobs have been scrapped.
Russia’s fiddling with gas flows to Europe could create an economic spillover effect, warns Germany’s top economy minister.
Downturns can bring a lot of pain, but they can also bring on plenty of opportunities, as lower stock prices start making costs of entry more attractive. Before taking advantage of these opportunities, however, investors need to find a recognizable signal that will set them apart. One popular signal to follow is the insider buying, the trades made by high-ranking company officers whose positions give them the ‘inside’ track on their company’s likely prospects – and therefore, of the stock’s pros
Weitz Investment Management, an investment management firm, published its “Partners III Opportunity Fund” first quarter 2022 investor letter – a copy of which can be downloaded here. The Partners III Opportunity Fund’s Institutional Class returned -5.09% in the first quarter of 2022 compared with -4.60% for the S&P 500 and -5.28% for the Russell 3000. […]
Yahoo Finance Live's Dave Briggs looks at the potential delays Intel's Ohio factory may face due to the CHIPS Act passed by Congress.